Evidence map›Paper›PMID 42336819›Full record

ArticleNature communications2026

Stromal and endothelial transcriptional changes during progression from MGUS to myeloma and after treatment response.

Itziar Cenzano, Miguel Cócera, Marta Larrayoz, Lorea Campos-Dopazo, Sonia Sanz, Azari Bantan, Amaia Vilas-Zornoza, Patxi San-Martin, Paula Aguirre-Ruiz, Diego Alignani and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Itziar Cenzano *Hematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.ORCID http://orcid.org/0000-0002-9030-3069
Miguel Cócera *Hematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.ORCID http://orcid.org/0000-0002-5679-1206
Marta LarrayozHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.ORCID http://orcid.org/0000-0001-6097-8244
Lorea Campos-DopazoHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.
Sonia SanzHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.
Azari BantanDivision of Biomedical Sciences, King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia.
Amaia Vilas-ZornozaHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.
Patxi San-MartinHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.ORCID http://orcid.org/0000-0003-1483-4279
Paula Aguirre-RuizHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.
Diego AlignaniHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.
Aitziber LopezHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.
Ignacio Sancho GonzálezHospital Reina Sofía de Tudela, Tudela, Spain.ORCID http://orcid.org/0000-0002-1077-0354
Javier RuizHospital Universitario de Navarra, Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain.ORCID http://orcid.org/0000-0001-6450-6375
Purificacion Ripalda-CemborainHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.ORCID http://orcid.org/0000-0001-8425-3563
Marta Abengozar-MuelaDepartament of Pathology, Clinica Universidad de Navarra, Pamplona, Spain.
Emma Muiños-LópezHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.ORCID http://orcid.org/0000-0002-6618-4135
Vincenzo LaganiDivision of Biomedical Sciences, King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia.ORCID http://orcid.org/0000-0002-6552-6076
Jesper TegnerDivision of Biomedical Sciences, King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia.ORCID http://orcid.org/0000-0002-9568-5588
Mikel HernáezCentro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain.ORCID http://orcid.org/0000-0003-0443-2305
Xabier AgirreHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.ORCID http://orcid.org/0000-0002-6558-9560
Benjamin EbertDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0197-5451
Bruno PaivaHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.ORCID http://orcid.org/0000-0003-1977-3815
Paula Rodriguez-OteroCentro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain.ORCID http://orcid.org/0000-0001-5236-7785
Luis-Esteban Tamariz-AmadorCentro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain.ORCID http://orcid.org/0000-0002-4088-0992
Jesús San-MiguelCentro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain.ORCID http://orcid.org/0000-0002-9183-4857
Borja SaezHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.ORCID http://orcid.org/0000-0001-7908-7089
José A Martinez-ClimentHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.ORCID http://orcid.org/0000-0002-7938-3950
Isabel A CalvoHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain. icalvoa@unav.es.ORCID http://orcid.org/0000-0001-6619-4571
David Gomez-CabreroDivision of Biomedical Sciences, King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia. david.gomezcabrero@kaust.edu.sa.ORCID http://orcid.org/0000-0003-4186-3788
Felipe ProsperHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain. fprosper@unav.es.ORCID http://orcid.org/0000-0001-6115-8790

Funding

Cancer Research UK (CRUK) C355/A26819Departamento de Educación, Gobierno de Navarra (Department of Education, Government of Navarra) AGATA 0011-1411-2020-000010/0011-1411-2020-000011European Commission (EC) H2020- MSCA-IF-837491Ministerio de Educación, Cultura y Deporte (Ministry of Education, Culture and Sports, Spain) PID2019-111192GA-I00 (MICINN)
6 · The paper itself

Abstract

Progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) is accompanied by profound remodeling of the bone marrow microenvironment (BME), yet the contribution of its non-immune compartment remains unclear. Using single-cell RNA sequencing in genetically engineered mouse models that recapitulate disease evolution, we transcriptionally profile endothelial cells (EC) and mesenchymal stem cells (MSC). EC adopt a stress-associated program at MGUS that precedes angiogenesis in MM, while MSC undergo early and sustained loss of differentiation capacity. We identify a coordinated interferon (IFN)-driven program across EC and MSC that defines MM in the BIcγ1 model but is absent in the more aggressive MI

Indexed as

Endothelial CellsMonoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaAnimalsBone MarrowBortezomibCell DifferentiationDexamethasoneDisease Models, AnimalDisease ProgressionHumansInterferonsLenalidomideMesenchymal Stem CellsMiceNeovascularization, PathologicBortezomibDexamethasoneInterferonsLenalidomide

Identifiers

PMID42336819
PMCPMC13443197

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.